TBR-065

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameTBR-065
Drug Alias NameTBR-065BIM-23B065
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionDopamine D2 receptor agonistsSomatostatin receptor 2 agonists
TargetsDopamine D2 receptorSomatostatin receptor 2
Therapy Area/IndicationsAcromegaly
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUkraineSerbia +[4
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIpsen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIpsenTiburio Therapeutics
Active IndicationsN/A
Inactive IndicationsAcromegaly

Other Information

ATC CodeN/A
Related LinksN/A